It has been proposed that metformin exerts its anti-cancer properties through direct effects on cancer cells, particularly through inhibition of the AMPK/mTOR pathway, and indirect effects by decreasing glucose, insulin, insulin-like growth factor 1 (IGF-1) levels, and other inflammatory factors [9]. Here, INS is linked to cancer.